Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

A Study to Predict Atrial Fibrillation (AF) Burden in Participants With PAF and PsAF Treated With the VARIPULSE™ PFA Catheter

NCT: NCT07788989 · NOT_YET_RECRUITING

NCT IDNCT07788989
StatusNOT_YET_RECRUITING
Start Date2026-10-30
Completion2029-10-31
SponsorBiosense Webster, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The purpose of this study is to evaluate how safe VARIPULSE™ Catheter is and how well it works in the treatment of participants with symptomatic paroxysmal atrial fibrillation (PAF; irregular heartbeat where episodes start and stop on their own, usually within seven days) and symptomatic persistent atrial fibrillation (PsAF; irregular, rapid heartbeat that lasts more than 7 days and doesn't stop on its own).

Frequently Asked Questions

What is A Study to Predict Atrial Fibrillation (AF) Burden in Participants With PAF and PsAF Treated With the VARIPULSE™ PFA Catheter?

A Study to Predict Atrial Fibrillation (AF) Burden in Participants With PAF and PsAF Treated With the VARIPULSE™ PFA Catheter is a clinical trial registered under NCT07788989. Current status: NOT_YET_RECRUITING.

What is the status of NCT07788989?

The current status of NCT07788989 (A Study to Predict Atrial Fibrillation (AF) Burden in Participants With PAF and PsAF Treated With the VARIPULSE™ PFA Catheter) is: NOT_YET_RECRUITING.

When did A Study to Predict Atrial Fibrillation (AF) Burden in Participants With PAF and PsAF Treated With the VARIPULSE™ PFA Catheter start?

A Study to Predict Atrial Fibrillation (AF) Burden in Participants With PAF and PsAF Treated With the VARIPULSE™ PFA Catheter started on 2026-10-30.

Related Devices

PMA P210027Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillationBiosense Webster, Inc. PMA P240006Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible ElectroporationBiosense Webster, Inc. K201750Pentaray Nav eco High-Density Mapping CatheterBiosense Webster, Inc. K231312PENTARAY® NAV ECO High Density Mapping Catheter, DECANAV® Mapping Catheter, Webster® CS Catheter with Auto ID, Webster® CS Catheter with EZ Steer Technology, Webster® CS Catheter with EZ Steer Technology with Auto IDBiosense Webster, Inc. PMA P010068catheter, percutaneous, cardiac ablation, for treatment of atrial flutterBiosense Webster, Inc.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑